| Size | Price | |
|---|---|---|
| 5g | ||
| Other Sizes |
| Targets |
NDSB 256-4T is a non-detergent sulfobetaine that does not have specific biological receptors as its primary targets. Its mechanism of action is based on its ability to prevent protein aggregation and facilitate protein folding, presumably by interacting with early folding intermediates. The compound's zwitterionic nature allows it to stabilize proteins without denaturing them, making it useful for protein biochemistry applications. Its primary applications are as a protein stabilization reagent, particularly in protein purification, refolding, and crystallization studies.
|
|---|---|
| ln Vitro |
In vitro, NDSB 256-4T is used as a biochemical reagent and non-detergent sulfobetaine for life science research. It inhibits protein aggregation and aids in protein folding by interacting with early folding intermediates. The compound is used in protein biochemistry applications, including protein purification, refolding, and crystallization. Cellular assays are not typically performed with this compound as a direct cell-modulating agent, as its primary applications are in protein biochemistry. The compound's ability to stabilize proteins makes it valuable for studying protein structure and function.
|
| ln Vivo |
In vivo data for NDSB 256-4T is limited, as it is primarily used as an in vitro research reagent for protein biochemistry. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Its primary applications are in protein purification, refolding, and crystallization studies. The compound's ability to stabilize proteins suggests potential for in vivo applications in protein therapeutics, though specific data is not available. The compound is not a therapeutic agent.
|
| Enzyme Assay |
In vitro assays for NDSB 256-4T typically evaluate its ability to prevent protein aggregation and facilitate protein folding. A standard protocol involves incubating a model protein (e.g., lysozyme, BSA) with varying concentrations of NDSB 256-4T (typically 0.1-1 M) in appropriate buffer systems. Protein aggregation is monitored by light scattering or size exclusion chromatography. Protein folding is assessed by measuring enzymatic activity, circular dichroism, or fluorescence spectroscopy. The compound's ability to stabilize proteins against thermal or chemical denaturation is evaluated by measuring thermal melting temperature (Tm) using differential scanning calorimetry or circular dichroism.
|
| Cell Assay |
Cellular assays for NDSB 256-4T are not typically performed, as it is primarily a protein biochemistry reagent rather than a cell-modulating agent. The compound is used in cell lysis and protein extraction buffers to stabilize proteins during purification. A typical protocol involves adding NDSB 256-4T to lysis buffers at concentrations of 0.5-1 M. Cells are lysed and proteins are extracted. Protein yield and activity are compared with and without NDSB 256-4T. The compound's ability to prevent protein aggregation during cell lysis is evaluated. Cytotoxicity is not typically assessed as the compound is used in cell-free systems.
|
| Animal Protocol |
In vivo animal studies for NDSB 256-4T are not standard, as it is primarily a protein biochemistry reagent rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to evaluating the compound as a formulation excipient for protein therapeutics. The compound's primary value lies in its use for protein purification and stabilization in research settings. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for NDSB 256-4T is limited, as it is primarily a research reagent. The compound has a molecular weight of 257.35 g/mol and a molecular formula of C₁₂H₁₉NO₃S. It is a solid at room temperature. As a zwitterionic sulfobetaine, it is expected to have limited membrane permeability. The compound is soluble in water and aqueous buffers. Specific ADME data is not available. The compound is stored in a dry, cool place.
|
| Toxicity/Toxicokinetics |
NDSB 256-4T is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
NDSB 256-4T (3-(4-(tert-Butyl)pyridinio)-1-propanesulfonate, CAS 570412-84-9) is a biochemical reagent with the molecular formula C₁₂H₁₉NO₃S. It is a non-detergent sulfobetaine that inhibits protein aggregation and aids in protein folding. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent.
|
| Molecular Formula |
C12H19NO3S
|
|---|---|
| Molecular Weight |
257.35
|
| Exact Mass |
383.249
|
| CAS # |
570412-84-9
|
| PubChem CID |
16760575
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.363
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])([H])C([H])([H])[N+]1C([H])=C([H])C(=C([H])C=1[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])(=O)(=O)[O-]
|
| InChi Key |
QMGYGZCGWOKPGR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H19NO3S/c1-12(2,3)11-5-8-13(9-6-11)7-4-10-17(14,15)16/h5-6,8-9H,4,7,10H2,1-3H3
|
| Chemical Name |
3-(4-tert-butylpyridin-1-ium-1-yl)propane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8858 mL | 19.4288 mL | 38.8576 mL | |
| 5 mM | 0.7772 mL | 3.8858 mL | 7.7715 mL | |
| 10 mM | 0.3886 mL | 1.9429 mL | 3.8858 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
